First US patient enrolled in Abivax’s phase 3 trial of obefazimod for ulcerative colitis

Abivax announced that the first U.S. patient has been enrolled in its global phase 3 clinical trial of its oral small-molecule inhibitor obefazimod for the treatment of moderate to severe ulcerative colitis.The trial will include two induction studies – ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) – and a subsequent ABTECT maintenance trial (ABX464-107) that will investigate 25 mg and 50 mg doses of obefazimod for the treatment of patients with UC who are either naïve to or previously failed advanced therapies.“As the principal investigator in the U.S., I am excited aboutRead More